Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: knee

Inflammation May Sensitize Patients with Osteoarthritis to Pain

Lara C. Pullen, PhD  |  May 30, 2016

A recent editorial in Arthritis & Rheumatology explored the role of sensitization, not nociception, as a key mechanism of pain for patients with knee OA, as well as inflammation’s role in pain perception. Recent research of synovitis and joint effusion supports the idea that early prevention or treatment of sensitization may be paramount to reducing long-term pain in patients with knee OA…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & RheumatologyJoint PainkneeKnee Osteoarthritis (OA)osteoarthritis (OA)Painsynovitis

Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain

Michele B. Kaufman, PharmD, BCGP  |  May 25, 2016

Recent clinical trials have evaluated the efficacy of GSK3196165, a monoclonal antibody, and fasinumab, a nerve growth factor antibody, in treating patients with osteoarthritis and pain…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:fasinumabhandhand painKnee Osteoarthritis (OA)monoclonal antibodyosteoarthritis (OA)Pain

Rheumatology Coding Corner Question: Documentation Improvement

From the College  |  May 13, 2016

A 55-year-old female patient returns for her second infliximab infusion. Her temperature is 98°F, her height is 5’6″ and her weight is 151 lbs. She received 210 mg infliximab via infusion. The patient arrived at the clinic at 8:15 a.m. and left at 10:55 a.m. Can this encounter be coded correctly? Yes No A 38-year-old…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingPractice Managementrheumatologistrheumatology

Rheumatology Coding Corner Answer: Documentation Improvement

From the College  |  May 13, 2016

Take the challenge. B—No. Although the documentation states the patient arrived at the clinic at 8:15 a.m. and left the clinic at 10:55 a.m., it does not document the actual start and stop times of the infusion. According to CPT, when reporting codes for which infusion time is a factor, use the actual time over…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingPractice Managementrheumatologistrheumatology

Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More

Michele B. Kaufman, PharmD, BCGP  |  May 13, 2016

April 5, 2016, marks a revolutionary day in the treatment of autoimmune diseases: The U.S. Food and Drug Administration (FDA) approved an infliximab (Remicade) biosimilar, known as Inflectra (infliximab-dyyb). Infliximab-dyyb, which is administered by intravenous infusion, is the first biosimilar drug approved to treat rheumatic disease in the U.S.1 Infliximab-dyyb has received approval for almost…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:ApprovalsBiologicsBiosimilarsdrugFDAInflectrainfliximabRemicadeResearchrheumatologySafetyZirletta

Study Associates Higher Risks with Total Joint Arthroplasty among Patients with Hepatitis C

Catherine Kolonko  |  May 13, 2016

A study that looked at the impact of hepatitis C on short-term outcomes of total joint arthroplasty found an increase in co-morbidity compared with patients without the liver disease. The number of people in need of total joint arthroplasty is expected to rise in conjunction with an aging population and advances in hepatitis C treatments….

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:hepatitis COutcomespatient carerisktotal join arthroplasty

Tips for Increasing Your Client Base

Karen Appold  |  May 13, 2016

Recruiting new patients requires a multi-faceted approach. A rheumatologist must have a solid brand and marketing platform, as well as an active strategy to attract and convert new patients. This might involve embracing social media, having a website, developing a referral network, being involved in your community and nurturing existing patients. Your brand includes such…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:patient carePatientsPractice Managementrheumatology

Rheumatology Coding Corner Question: Coding & Billing Basics

From the College  |  April 15, 2016

When reporting E/M service levels, if time spent counseling and/or coordinating care dominates the session, which of the following is true? Total time must be documented Greater than 50% of the time must be for face-to-face counseling and/or coordinating care The extent of the counseling and/or coordinating care must be documented All of the above…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingPractice Managementrheumatologistrheumatology

Rheumatology Coding Corner Answer: Coding & Billing Basics

From the College  |  April 15, 2016

Take the challenge. 1. D: All of the above Rationale: Per CPT, if time spent counseling and/or coordinating care dominates the session, then total time must be documented; greater than 50% of the time must be for face-to-face counseling and/or coordinating care, and must be documented as such. Additionally, the extent of the counseling and/or…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingPractice Managementrheumatologistrheumatology

Diagnostic Imaging in Patient with Chronic Left Ankle Pain: Findings

Cianna Leatherwood, MD, & Derrick J. Todd, MD, PhD  |  April 15, 2016

Radiographic imaging showed circumferential soft tissue swelling of the ankle with a soft-tissue density seen in the tibiotalar and posterior subtalar joints, as well as a large, lobulated effusion. MRI of the left ankle shows cystic changes within the talus and first cuneiform bones, as well as a lobulated abnormal soft tissue density with low…

Filed under:ConditionsSoft Tissue Pain Tagged with:anklediagnosticfootimagingMRIPainradiographyrheumatologyswelling

  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 78
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences